The firm maintains an asset-light structure with net PPE declining to $119.9K in 2026Q1, while equity has been severely eroded by an accumulated deficit reaching $116.5 million.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 5.38M | 4.94M | 2.73M | 3.58M | 18.43M | 17.74M | 2.28M | 7.6M | 10.06M | 14.64M | 10.06M | 7.18M | 5.08K | 4.47K | 5.6K | 22.45K | 1.13K | 1.79K | 69.67K | 1.61M | 328.84K | 739.97K | 1.27M | 970.64K | 1.44M | 1.45M | 2M | 1.75M | 472.4K | 1.92M | 2.97M |
| Cash & Short-Term Investments | 4.91M | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M | 1.58M | 431.4K | 1.37M | 4.88M | 1.46M | 1.96M | 5.08K | 249 | 1.38K | 18.23K | 1.13K | 1.79K | 66.83K | 1.58M | 228.94K | 550.63K | 871.15K | 589.8K | 858.73K | 869.48K | 1.47M | 1.02M | 264.05K | 577.41K | 1.59M |
| Cash Only | 4.91M | 4.68M | 2.24M | 2.29M | 17.72M | 17.36M | 1.58M | 431.4K | 1.37M | 4.88M | 1.38M | 1.88M | 5.08K | 249 | 1.38K | 18.23K | 1.13K | 1.79K | 66.83K | 582.02K | 228.94K | 550.63K | 871.15K | 589.8K | 858.73K | 869.48K | 1.47M | 1.02M | 264.05K | 577.41K | 1.59M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 82.91K | 82.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 224.61K | 0 | 0 | 0 | 6.38M | 7.87M | 8.84M | 8.06M | 4.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74.83K | 155.23K | 325.71K | 345.41K | 499.02K | 442.56K | 506.56K | 687.6K | 134.63K | 911.5K | 820.86K |
| Days Sales Outstanding | - | - | - | - | - | - | - | 58.38 | 66.82 | 66.39 | 81.39 | 111.31 | - | - | - | - | - | - | - | - | 81.97 | 47.52 | 107.5 | 99.33 | 98.14 | 100.72 | 83.97 | 151.15 | 29.26 | 119.62 | 148.02 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20K | 0 | 12.99K | 7.99K | 93.25K | 296.54K |
| Days Inventory Outstanding | 38 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 97.22 | 21.74 | 148.15 | 583.36 |
| Other Current Assets | 0 | 43.25K | 0 | 567.6K | 159.78K | 0 | 700.71K | 718.53K | 818.6K | 924.27K | 542.24K | 343.81K | 0 | 4.22K | 4.22K | 4.22K | 0 | 0 | 0 | 22.99K | 25.07K | 34.1K | 0 | 0 | 0 | 0 | 26.46K | 22.64K | 0 | 146.53K | 0 |
| Total Non-Current Assets | 146.37K | 159.23K | 347.96K | 718.31K | 1.12M | 8.98M | 1.82M | 17.41M | 19.58M | 37.55M | 29.44M | 6.66M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 134.74K | 156.95K | 196.24K | 234.51K | 305.17K | 307.82K | 456.02K | 372.77K | 421.05K | 1.24M | 1.18M |
| Property, Plant & Equipment | 119.93K | 159.23K | 305.78K | 507.38K | 741.3K | 470.73K | 0 | 83.13K | 58.89K | 95.05K | 100.24K | 73.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.48K | 18.4K | 29.53K | 42.02K | 70.84K | 50.59K | 108.06K | 132.8K | 184.14K | 586.96K | 622.86K |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | 480.16x | 730.12x | 511.25x | 360.59x | 218.66x | - | - | - | - | - | - | - | - | 95.83x | 64.80x | 37.45x | 30.21x | 26.20x | 31.70x | 20.38x | 12.50x | 9.12x | 4.74x | 3.25x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 1.59M | 0 | 13.73M | 13.73M | 21.9M | 17.09M | 3.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 42.18K | 210.93K | 379.69K | 6.92M | 1.82M | 3.58M | 5.78M | 9.47M | 8.76M | 3.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 131.26K | 138.55K | 166.71K | 192.49K | 225.86K | 255.73K | 302.79K | 687.6K | 134.63K | 911.5K | 820.86K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 26.44K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.18M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.47K | 1.51K | 45.17K | 32.18K | 0 | 0 | 100.83K |
| Total Assets | 5.52M | 5.1M | 3.08M | 4.3M | 19.55M | 26.72M | 4.1M | 25.01M | 29.64M | 52.2M | 39.51M | 13.83M | 5.08K | 4.47K | 5.6K | 22.45K | 1.13K | 1.79K | 69.67K | 1.61M | 463.58K | 896.92K | 1.46M | 1.21M | 1.75M | 1.75M | 2.46M | 2.12M | 893.45K | 3.17M | 4.14M |
| Asset Turnover | 0.00x | - | - | - | - | - | - | 1.60x | 1.45x | 0.93x | 0.91x | 1.15x | - | - | - | - | - | - | - | 0.47x | 0.72x | 1.33x | 0.76x | 1.05x | 1.06x | 0.91x | 0.90x | 0.78x | 1.88x | 0.88x | 0.49x |
| Asset Growth % | 23.23% | 65.32% | -28.31% | -78.01% | -26.82% | 552.18% | -83.62% | -15.63% | -43.22% | 32.12% | 185.57% | 271973.43% | 13.81% | -20.21% | -75.06% | 1893.78% | -37.17% | -97.43% | -95.66% | 246.22% | -48.31% | -38.74% | 21.48% | -30.97% | -0.41% | -28.65% | 16.01% | 137.06% | -71.77% | -23.57% | -5.88% |
| Total Current Liabilities | 460.68K | 918.4K | 1.49M | 2.34M | 4M | 2.08M | 681.25K | 14.38M | 14.69M | 30.37M | 12.71M | 8.58M | 8.96K | 24.7K | 25.67K | 17.89K | 50.64K | 11.87K | 21.21K | 47.9K | 87.08K | 179.52K | 665.13K | 177.99K | 315.98K | 341.54K | 806.35K | 1.35M | 2.45M | 1.61M | 873.32K |
| Accounts Payable | 280.31K | 581.02K | 521.75K | 1.22M | 463.27K | 683.39K | 681.25K | 4.7M | 4.38M | 5.32M | 5.13M | 2.6M | 0 | 0 | 0 | 0 | 2.64K | 11.87K | 5.21K | 900 | 32.14K | 14.2K | 71.87K | 21.47K | 39.03K | 14.87K | 51.78K | 234.12K | 335.78K | 651.38K | 403.87K |
| Days Payables Outstanding | 1.5K | 1.06K | 564.28 | 1.09K | 388.55 | 365.95 | 2.06K | 53.97 | 46.98 | 50.67 | 63.25 | 92.71 | - | - | - | - | - | - | - | 5.19 | 13.08K | 48.85 | 235.5 | 64 | 109.14 | 56.09 | 116.49 | 1.75K | 913.34 | 1.03K | 794.51 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.88M | 5.21M | 4.8M | 3.49M | 1.24M | 0 | 2K | 8K | 0 | 0 | 0 | 0 | 9.68K | 9.67K | 10.44K | 66.25K | 37.5K | 112.5K | 112.5K | 33.74K | 351.89K | 872.29K | 464.27K | 136.3K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -2.58M | 0 | 44.84K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 391.39K | 0 | 0 | 41.2K | 0 | 344.25K | 454.97K | 0 | 0 |
| Other Current Liabilities | 123.57K | 251.51K | 3.09K | 350.72K | 1.76M | 0 | 0 | 737.79K | 3.8M | 20.24M | 564.24K | 3K | 0 | 0 | 0 | 17.89K | 40K | 0 | 0 | 36K | 42.1K | 106.79K | 0 | 0 | 0 | 100K | 720.83K | 419.6K | 783.89K | 0 | 0 |
| Current Ratio | 11.67x | 5.38x | 1.84x | 1.53x | 4.61x | 8.51x | 3.35x | 0.53x | 0.68x | 0.48x | 0.79x | 0.84x | 0.57x | 0.18x | 0.22x | 1.25x | 0.02x | 0.15x | 3.29x | 33.51x | 3.78x | 4.12x | 1.91x | 5.45x | 4.56x | 4.23x | 2.48x | 1.29x | 0.19x | 1.20x | 3.40x |
| Quick Ratio | 11.67x | 5.38x | 1.84x | 1.53x | 4.61x | 8.51x | 3.35x | 0.53x | 0.68x | 0.48x | 0.79x | 0.84x | 0.57x | 0.18x | 0.22x | 1.25x | 0.02x | 0.15x | 3.29x | 33.51x | 3.78x | 4.12x | 1.91x | 5.45x | 4.56x | 4.29x | 2.48x | 1.28x | 0.19x | 1.14x | 3.06x |
| Cash Conversion Cycle | -1.46K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.5K | -862.34 | -767.12 | -63.13 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 2.33M | 0 | 0 | 4.19M | 2.38M | 15.14M | 5M | 0 | 2K | 8K | 0 | 2.64K | 11.87K | 5.21K | 10.58K | 41.81K | 24.64K | 1.18K | 71.77K | 1.03K | 127.37K | 85.52K | 0 | 1.21M | 33.36K | 540.17K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.38M | 1.54M | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70.75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 68.86K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 2.26M | 0 | 0 | 4.19M | 0 | 13.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.18K | 1.03K | 1.03K | 0 | 0 | 0 | 0 | 33.36K | 0 |
| Total Liabilities | 460.68K | 918.4K | 1.49M | 2.34M | 4M | 4.41M | 681.25K | 14.38M | 18.88M | 32.75M | 27.84M | 13.58M | 8.96K | 24.7K | 25.67K | 17.89K | 50.64K | 11.87K | 21.21K | 47.9K | 87.08K | 179.52K | 666.31K | 249.77K | 317.01K | 341.54K | 806.35K | 1.35M | 2.45M | 1.64M | 873.32K |
| Total Debt | 0 | 0 | 0 | 0 | 63.82K | 176.3K | 0 | 4.88M | 5.21M | 7.18M | 5.03M | 6.24M | 0 | 2K | 8K | 0 | 0 | 0 | 0 | 9.68K | 9.67K | 10.44K | 66.25K | 108.25K | 112.5K | 112.5K | 33.74K | 351.89K | 872.29K | 464.27K | 136.3K |
| Net Debt | -4.91M | -4.68M | -2.24M | -2.29M | -17.66M | -17.18M | -1.58M | 4.45M | 3.84M | 2.3M | 3.65M | 4.36M | -5.08K | 1.75K | 6.62K | -18.23K | -1.13K | -1.79K | -66.83K | -572.34K | -219.27K | -540.19K | -804.9K | -481.55K | -746.23K | -756.98K | -1.43M | -670.11K | 608.24K | -113.14K | -1.45M |
| Debt / Equity | 0.00x | - | - | - | 0.00x | 0.01x | - | 0.46x | 0.48x | 0.37x | 0.43x | 24.12x | - | - | - | - | - | - | - | 0.01x | 0.03x | 0.01x | 0.08x | 0.11x | 0.08x | 0.08x | 0.02x | 0.46x | - | 0.30x | 0.04x |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94x | - | 0.08x | 0.63x | - | - | - |
| Net Debt / EBITDA | 0.61x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.23x | - | -3.23x | -1.20x | - | - | - |
| Interest Coverage | -12000.31x | -82777.81x | - | -4655.56x | -3801.13x | -5469.31x | -14.42x | -6.55x | -13.45x | -18.94x | -7.69x | -2.95x | - | - | - | - | - | - | -10.97x | - | -156.02x | -17.15x | -28.57x | -35.98x | 7.08x | - | 10.50x | 5.09x | -0.50x | - | - |
| Total Equity | 5.06M | 4.18M | 1.59M | 1.96M | 15.56M | 22.31M | 3.42M | 10.62M | 10.76M | 19.44M | 11.66M | 258.53K | -3.87K | -20.23K | -20.07K | 4.55K | -49.52K | -10.07K | 48.47K | 1.56M | 376.5K | 717.4K | 797.74K | 955.38K | 1.43M | 1.41M | 1.65M | 768.14K | -1.55M | 1.53M | 3.27M |
| Equity Growth % | 119.34% | 162.28% | -18.58% | -87.42% | -30.26% | 553.05% | -67.84% | -1.28% | -44.67% | 66.71% | 4411.49% | 6778.71% | 80.86% | -0.8% | -540.53% | 109.2% | -391.47% | -120.79% | -96.89% | 313.57% | -47.52% | -10.07% | -16.5% | -33.14% | 1.22% | -14.49% | 114.89% | 149.45% | -201.86% | -53.33% | -11.68% |
| Book Value per Share | 3.35 | 12.48 | 38.01 | 10.87 | 89.83 | 566.69 | 356.20 | 4821.40 | 27169.44 | 77779.20 | 53503.22 | 1397.48 | -35.19 | -183.88 | -182.42 | 41.41 | -450.15 | -91.59 | 440.63 | 14155.50 | 3422.74 | 6521.84 | 7252.14 | 8685.26 | 12989.38 | 12832.44 | 15006.14 | 6983.06 | -14122.64 | 13864.66 | 29707.94 |
| Total Shareholders' Equity | 5.06M | 4.18M | 1.59M | 1.96M | 14.67M | 22.31M | 3.42M | 10.62M | 10.76M | 19.44M | 11.66M | 258.53K | -3.87K | -20.23K | -20.07K | 4.55K | -49.52K | -10.07K | 48.47K | 1.56M | 376.5K | 717.4K | 797.74K | 955.38K | 1.43M | 1.41M | 1.65M | 768.14K | -1.55M | 1.53M | 3.27M |
| Common Stock | 18.88K | 10.62K | 6.78K | 27.39K | 20.78K | 6.52K | 100.95K | 25.22K | 423.29K | 181.63K | 138.86K | 118.74K | 154.1K | 121.42K | 121.42K | 121.42K | 65K | 650K | 650K | 650K | 469.77K | 469.77K | 469.75K | 470.16K | 474.07K | 474.07K | 470.88K | 461.75K | 258.42K | 214.1K | 191.15K |
| Retained Earnings | -116.48M | -114.85M | -106.07M | -96.5M | -79.21M | -60.74M | -11.76M | -40.51M | -34.48M | -15M | -3.83M | -1.05M | -47.43M | -47.39M | -47.39M | -47.37M | -47.33M | -47.29M | -45.87M | -45.73M | -46.54M | -46.18M | -46.1M | -45.94M | -45.45M | -45.47M | -45.23M | -45.61M | -45.96M | -40.17M | -35.45M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -587.06K | -580.04K | -594.52K | -569.75K | -536.73K | -30.8K | -181.28K | 60.01K | 87K | 36.88K | -7.43K | 0 | 0 | 0 | 0 | 0 | -65K | 0 | -1.36M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 885.03K | 0 | 0 | 0 | 0 | 0 | 3.38K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and dilution risk
As reported in financial statements, Enveric Biosciences maintains a cash balance of $4.68 million, which, when measured against consistent quarterly burn rates, suggests a limited operational runway that may force the company to seek dilutive capital infusions or strategic partnerships to sustain its research activities.
The current ratio of 11.67 appears artificially high due to the lack of significant current liabilities rather than an abundance of liquid assets. Investors should monitor this metric closely, as the company's inability to generate internal cash flow makes it highly sensitive to capital market conditions.
Based on the provided balance sheet data, Enveric's asset composition is heavily skewed toward cash and minimal tangible property, with net PPE declining from $507.4K in 2023Q4 to $119.9K in 2026Q1, indicating an asset-light model that prioritizes intellectual property development over physical infrastructure investment.
The absence of significant goodwill or capitalized intangible assets on the balance sheet suggests that the company's core value, its Psybrary platform, is largely expensed through the income statement rather than reflected in book value. This accounting treatment may obscure the true economic value of the company's proprietary chemical library.
According to recent SEC filings, the company's equity base has been consistently eroded by accumulated deficits, which reached $116.5 million as of 2026Q1, reflecting the ongoing financial strain of funding pre-clinical biotechnology development without the benefit of offsetting product revenue or commercial milestones.
The persistent negative retained earnings highlight the long-term capital intensity of the business model. Shareholders should remain cautious regarding the potential for further dilution, as the company appears to rely on equity issuance to replenish the equity base and fund its ongoing research operations.
As indicated by the historical data, the company's reliance on equity-based financing to maintain its balance sheet health creates a structural risk where the book value of equity may not accurately represent the long-term viability of the firm's underlying intellectual property assets.
The volatility in total assets and equity over the last ten quarters suggests that the balance sheet is highly reactive to financing events rather than operational progress. This pattern warrants further investigation into whether the company can achieve a sustainable capital structure before its current cash reserves are exhausted.
Quick answers to the most common questions about buying ENVB stock.
As of 2025, Enveric Biosciences, Inc. (ENVB) had total assets of $5.1M including $4.9M in current assets.
Enveric Biosciences, Inc. (ENVB) carries total debt of $0.0M, offset by $4.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Enveric Biosciences, Inc. (ENVB) has total shareholders' equity (book value) of $4.2M ($12.48 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Enveric Biosciences, Inc. (ENVB) reported a current ratio of 5.38x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.